获取途径

作者

Yanling Guo Yaoyao Zhu Ran Zhang Shuangyan Yang Lucyna Kepka Gustavo Arruda Viani Michael T. Milano Terence T. Sio Xiaojiang Sun Hongyu Wu Ligang Xing Yaping Xu

作者单位

Department of Radiation Oncology，Shanghai Pulmonary Hospital，Tongji University Medical School Cancer Institute，Tongji University School of Medicine，Shanghai，China；School of Medicine，Tongji University，Shanghai，China；Department of Radiation Oncology，Shanghai Pulmonary Hospital，Tongji University Medical School Cancer Institute，Tongji University School of Medicine，Shanghai，China；Department of Radiation Oncology，Shanghai Pulmonary Hospital，Tongji University Medical School Cancer Institute，Tongji University School of Medicine，Shanghai，China；School of Medicine，Tongji University，Shanghai，China；Department of Radiation Oncology，Shanghai Pulmonary Hospital，Tongji University Medical School Cancer Institute，Tongji University School of Medicine，Shanghai，China；Department of Radiotherapy，Military Institute of Medicine-National Research Institute，Warsaw，Poland；Department of Medical Imaging，Hematology and Oncology，Ribeirão Preto Medical School，University of São Paulo (FMRP-USP)，São Paulo，Brazil；Department of Radiation Oncology，University of Rochester Medical Center，Rochester，NY，USA；Department of Radiation Oncology，Mayo Clinic，Phoenix，AZ，USA；Department of Radiation Oncology，The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)，Institute of Basic Medicine and Cancer (IBMC)，Chinese Academy of Sciences，Hangzhou，China；Department of Radiation Oncology，Shanghai Pulmonary Hospital，Tongji University Medical School Cancer Institute，Tongji University School of Medicine，Shanghai，China；Department of Radiation Oncology，Shandong Key Laboratory of Radiation Oncology，Shandong Cancer Hospital and Institute，Shandong First Medical University and Shandong Academy of Medical Sciences，Jinan，China；Department of Radiation Oncology，Shanghai Pulmonary Hospital，Tongji University Medical School Cancer Institute，Tongji University School of Medicine，Shanghai，China

刊名

肺癌转化研究杂志

年份

2023

卷号

第12卷

期号

第6期

页码

1293-1302

关键词

Early-stage non-small cell lung cancer (early-stage NSCLC) patterns of failure stereotactic body radiotherapy (SBRT)

摘要

Background Stereotactic body radiotherapy has proven to provide high rates of tumor control for patients with early-stage non-small cell lung cancer . We are reporting a multicenter experience of long-term clinical outcomes and adverse effect profiles of patients with medically inoperable early-stage NSCLC treated with SBRT. Methods A total of 145 early-stage NSCLC patients underwent SBRT at the Cancer Hospital of the University of Chinese Academy of Sciences , Shandong Cancer Hospital and Inst...更多

Background Stereotactic body radiotherapy has proven to provide high rates of tumor control for patients with early-stage non-small cell lung cancer . We are reporting a multicenter experience of long-term clinical outcomes and adverse effect profiles of patients with medically inoperable early-stage NSCLC treated with SBRT. Methods A total of 145 early-stage NSCLC patients underwent SBRT at the Cancer Hospital of the University of Chinese Academy of Sciences , Shandong Cancer Hospital and Institute, and Shanghai Pulmonary Hospital between October 2012 and March 2019. Four-dimensional computed tomography simulation was used for all patients. All received a biologically effective dose of 96–120 Gy with the prescribed isodose line covering >95% of the planning target volume . Survival was analyzed by the Kaplan-Meier method. Survival was estimated using the Kaplan-Meier method. Results The median tumor diameter was 2.2 cm. The median follow-up was of 65.6 months. Thirty-five patients developed disease recurrence. The rates of local, regional, and distant disease recurrence were, respectively, 5.1%, 7.4%, and 13.2% at 3 years; and 9.6%, 9.8%, and 15.8% at 5 years. Progression-free survival rates at 3 and 5 years were 69.2% and 60.5% respectively; the overall survival rates were 78.1% and 70.1%, respectively. Five patients experienced grade 3 treatment-related adverse events . No patient experienced grade 4 or 5 toxicity. Conclusions From our retrospective analysis with long-term follow-up in Chinese population, SBRT achieved high rate of local control and low toxicity in patients with early-stage NSCLC. This study offered robust long-term outcome data of SBRT in the Chinese population, which was very rarely reported in China before.收起

文献类型

期刊

浏览量

5